May 31, 2016
New York City
The 5th Annual SeeThruEquity conference, held in New York City, will connect more than 50 presenting companies with microcap-focused investors, sponsors, and industry professionals in attendance. The conference will feature 30-minute presentations by presenting companies, as well as one-on-one meetings with investors. In addition to the large number of companies confirmed to present, SeeThruEquity is hosting a panel composed of industry leaders. For more information on SeeThruEquity, visit www.steconference.com
3TL Technologies (TTMZF)
3TL Technologies (OTC: TTMZF) is the creator of Platform3, a Software-as-a-Service (SaaS) consumer marketing platform that enables Consumer Packaged Goods (CPG) companies and consumer brands to engage shoppers through their mobile device and influence their purchasing decisions. Platform3 encompasses proprietary consumer engagement strategies and technology modules including optical character recognition (purchase receipt scanning), digital promotions, purchase data mining, loyalty and rewards. CPG companies and major retail brands use Platform3 to influence and incentivize shoppers to interact with their brand and make purchases in-store and online. For more information, visit the company's website at www.3tltechcorp.com.
Advanced Medical Isotope (ADMD)
Advanced Medical Isotope (OTC: ADMD) is a late-stage development company engaged in the development of brachytherapy devices for therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States. For more information, visit the company's website at www.isotopeworld.com.
Amarantus BioScience Holdings (AMBS)
Amarantus BioScience Holdings (OTC: AMBS) is a biotech company focused on developing therapeutic products with potential for orphan drug designation in neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company's lead therapeutic program is indicated for the treatment of problems associated with Parkinson's. It also haves exclusive worldwide license rights of Engineered Skin Substitute for severe burns. Amarantus' lead neurological diagnostic product is indicated to diagnose Alzheimer's disease. The company is actively exploring strategic options for Amarantus Diagnostics, including a potential spin-off, to derive the full value of its neuro-diagnostics business. For more information, visit the company's website at www.amarantus.com.
Apivio Systems (APVVF)
Apivio Systems (OTC: APVVF) is a Canadian technology company engaged in the design, development, marketing, and sale of communications equipment and software. It has a wholly owned Korean subsidiary with a history of supplying VoIP telephone equipment and other products to major Korean and international telecommunications carriers. The company develops Carrier grade VoIP phones for enterprise and residential markets and distributes them on ODM/OEM basis. Currently, Apivio is launching new product lines including its Android-based enterprise phone marketed with NEC America and portable Wi-Fi phones being sold through carriers and dealers. For more information, visit the company's website at www.apivio.com.
Avant Diagnostics (AVDX)
Avant Diagnostics (OTC: AVDX) is a medical diagnostic technology company that specializes in large panel biomarker tests. Its first test, OvaDx®, is proposed for use in monitoring women previously diagnosed with ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer. Avant intends to sell or license OvaDx® and to expand its portfolio of diagnostic tests in the future. For more information, visit the company's website at www.avantdiagnostics.com.
BIO-key International (BKYI)
BIO-key International (OTC: BKYI) provides of fingerprint biometric identification, secure mobile credentialing, and user identity verification solutions to reduce risk and protect the value of their services and assets. BIO-key's products are software-based and optimized to deliver fast and accurate user authentication on any device, network or Internet environment. These software products are compatible with more than 50 fingerprint readers. The company's technology is standards-compliant, independently validated by the National Institute of Standards & Technology (NIST), and hardware and operating system agnostic. For more information, visit the company's website at www.bio-key.com.
Blue Sphere (BLSP)
Blue Sphere (OTC: BLSP) is an international developer of waste-to-energy projects. The company seeks to own long-term cash generating assets in the waste-to-energy space through acquisitions, as well as through its proven Build-Own-Operate model. Blue Sphere waste-to-energy projects solve two pressing global problems. They provide a sustainable source of electricity and reduce the release of harmful methane gas into the atmosphere by using organic wastes (such as uneaten food) as its main feedstock. For more information please visit the company's website www.bluespherecorporate.com.
Calmare Therapeutics (CTTC)
Calmare Therapeutics (OTC: CTTC) researches, develops and commercializes chronic, neuropathic pain and wound affliction devices. The company's flagship medical device – the Calmare® Pain Therapy Device – is the only non-invasive and non-addictive modality that can successfully treat chronic, neuropathic pain. The company holds a FDA 510k clearance designation on its flagship device, which grants it the exclusive right to sell, market, research and develop the medical device in the United States. Calmare Devices are commercially sold to medical practices throughout the world. For more information, visit the company's website at www.calmaretherapeutics.com.
Cellectar Biosciences (CLRB)
Cellectar Biosciences (NASDAQ: CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company is also developing PDCs for targeted delivery of chemotherapeutics and plans to expand its PDC chemotherapeutic pipeline through in-house and collaborative R&D efforts. For additional information, visit the company's website at www.cellectarbiosciences.com.
ChineseInvestors.com (OTC: CIIX) provides real-time market commentary, analysis and educational-related services in Chinese language character sets (traditional and simplified), support services to its various partners, consultative services to smaller private companies considering becoming a public company, advertising and public relation related support services, and other services the company may identify as having the potential to create value or partnership opportunity with their existing services. For more information, visit the company's website at www.chinesefn.com.
COPsync (NASDAQ: COYN) operates the nation's only law enforcement real-time, information sharing network. The protection provided by COPsync has expanded to community buildings such as schools, banks, hospitals, energy companies and more. COPsync has developed a law enforcement real-time in-car information sharing, communication, and data interoperability network, which enables officers and agencies across the nation to communicate as if they were one large law enforcement department. The company has secured more than 1,200 customers in 10 states. For more information, visit the company's website at www.copsync.com.
DelMar Pharmaceuticals (DMPI)
DelMar Pharmaceuticals (NASDAQ: DMPI) is a clinical and commercial stage drug development company with a focus on the treatment of cancer in patients that are failing or have become intolerant to modern targeted or biologic treatments. The company's lead drug in development is undergoing clinical trials in the United States. Pre-clinical and clinical data suggest that it may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients. For more information, visit the company's website at www.delmarpharma.com.
Endonovo Therapeutics (ENDV)
Endonovo Therapeutics (OTC: ENDV) is a biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies. The company's initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform. For more information, visit the company's website at www.endonovo.com.
General Employment Enterprises (JOB)
General Employment Enterprises (NYSE: JOB) provides of specialized staffing solutions and is the successor to employment offices doing business since 1893. The company delivers professional staffing services and solutions in the information technology, engineering, finance and accounting specialties and light industrial staffing services through the names of General Employment, Access Data Consulting, Agile Resources, Ashley Ellis, Omni-One, Paladin Consulting and Triad. General Employment, through its Scribe Solutions brand, also staffs medical scribes who provide electronic medical records documentation for emergency room physicians and in medical practices. For more information, visit the company's website at www.generalemployment.com.
HealthWarehouse.com, Inc. (HEWA)
HealthWarehouse.com, Inc. (OTC: HEWA) is focused on the out-of-pocket prescription drug market, which is expected to grow to more than $80 billion in 2016. HealthWarehouse.com is currently one of less than 45 Verified Internet Pharmacy Practice Websites ("VIPPS") accredited by the National Association of Boards of Pharmacy and is the only VIPPS accredited pharmacy licensed in all 50 states that processes out-of-pocket prescriptions online. The company is a four-time winner of the BizRate Circle of Excellence Award for outstanding customer service and satisfaction, and was recognized by major consumer publications as having the lowest price among top U.S. pharmacies for commonly prescribed medications. For more information, visit the company's website at www.healthwarehouse.com.
HydroPhi Technologies Group (HPTG)
HydroPhi Technologies Group (OTC: HPTG) is a developer of water-based hydrogen fuel production systems. The company's technology isn't a fuel cell, nor is it a hydrogen alternative to traditional hydrocarbon fuels. The system utilizes distilled water for the production of hydrogen and oxygen, which is then injected into the air intake of an engine utilizing carbon-based fuels such as diesel, unleaded gasoline and natural gas. HydroPhi's system has been company tested showing up to 20% improved fuel efficiency while lowering greenhouse emissions up to 70%. For more information, visit the company's website at www.hydrophi.com.
IEG Holdings (IEGH)
IEG Holdings (OTC: IEGH) provides online unsecured consumer loans under the brand name, "Mr. Amazing Loans," via its website, www.mramazingloans.com. Offerings its services in 17 U.S. states, the company offers $5,000 loans over a term of five years at a 23.9% to 29.9% APR. IEG Holdings plans future expansion to 25 U.S. states during 2016. For more information, visit the company's website at www.investmentevolution.com.
International Western Petroleum (INWP)
International Western Petroleum (OTC: INWP) is a Texas-based E&P company that focuses on the acquisition, development, and exploration of crude oil and natural gas properties in Texas. The company is actively looking to acquire oil and gas properties and apply latest technologies and production know-how to increase production and reserves. IWP recently prospected and acquired several exploration projects in the prolific Bend Arch region, which is approximately 120 miles long and 40 miles wide. This area has been one of the most active drilling areas during the recent resurgence of United States drilling activities. For more information, visit the company's website at www.iwpetroleum.com.
NanoViricides (NYSE: NNVC) is a pre-clinical biotech company that has utilized its patented platform technology to rapidly create anti-viral drug candidates. Tests have been conducted on animals infected with various strains of influenza, HIV, dengue/dengue hemorrhagic fever, Ebola, rabies, adenovirus of the eye, as well as herpes infections of the skin and the eye without evidence of resistance, side effects or toxicity. Treatments for various forms of acute herpes infections are now being advanced through the pre-clinical process towards human trials. For more information, visit the company's website at www.nanoviricides.com.
O2Micro International (OIIM)
O2Micro International (NASDAQ: OIIM) develops and markets innovative power management components for the computer, consumer, industrial, automotive and communications markets. Products include LED general lighting, backlighting, battery management and power management. O2Micro maintains an extensive portfolio of intellectual property with more than 1,600 patents issued worldwide, and over 33,000 patent claims granted. The company maintains offices around the world. For more information, visit the company's website at www.o2micro.com.
PAR Technology (PAR)
Since 1978, PAR Technology (NYSE: PAR) has helped restaurant and retail customers put technology to work to improve internal operations, enhance customer experiences and better manage information. Today the company has point of sale systems in more than 50,000 restaurants and more than 110 countries. In addition, PAR provides technical solutions to the government sector through a wholly owned subsidiary comprised of PAR Government Systems Corporation and Rome Research Corporation. PAR's Government business delivers innovative information management solutions through advanced technology and professional services to federal, state, and local government agencies, as well as private industry customers throughout the world. For more information, visit the company's website at www.partech.com.
PCM (NASDAQ: PCMI) (formerly known as PC Mall, Inc.) is a technology solutions provider to businesses, government and educational institutions and individual consumers. The company markets its products, services and solutions through a 700+ sales force, field service teams and various direct marketing techniques. PCM offers multi-branded hardware solutions with a high degree of customization, and also facilitates an efficient supply chain and support mechanism for manufacturers by using a combination of direct marketing, centralized selling and support, and centralized product fulfillment. For more information please visit www.pcm.com.
Pivot Pharmaceuticals (PVOTF)
Pivot Pharmaceuticals (OTC: PVOTF) is a pharmaceutical company engaged in the development of novel therapies to address unmet medical needs in women's health. The company's focus is on innovative drugs that will provide new treatment options for women's cancers, as well as for unmet gynecological and urological problems. Pivot has a portfolio of novel anticancer candidates for treatment of gynecological and breast cancers and also is developing novel treatments to address lower urinary tract symptoms. For more information, visit the company's website at www.pivotpharma.com.
Predictive Technology Group (PRED)
Predictive Technology Group (OTC: PRED), through wholly owned subsidiaries, is engaged in the treatment of debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The company develops and acquires proprietary technologies that open windows into the origin of human illness and the role that genes and proteins play in the onset and progression of disease. PRED's subsidiaries use gene-based information in the development of new diagnostics that assess risk of illness and therapeutic products designed to prevent and treat diseases effectively. For more information, visit the company's website at www.predictivetechnologygroup.com.
Pressure BioSciences (PBIO)
Pressure BioSciences (OTC: PBIO) develops, markets and sells proprietary laboratory instrumentation and consumables to the life sciences sample preparation market. The company's products are based on the unique properties of both constant and alternating hydrostatic pressure. Its pressure cycling technology is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Pressure BioScience's primary application development and sales efforts are in the biomarker discovery and forensics areas. For more information, visit the company's website at www.pressurebiosciences.com.
Progressive Care (RXMD)
Progressive Care (OTC: RXMD), through its subsidiary, PharmCo, LLC, is a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities. For more information, visit the company's website at www.progressivecareus.com.
Rhino Resource Partners (RHNO)
Rhino Resource Partners (OTC: RHNO) is a diversified energy limited partnership that is focused on coal and energy related assets and activities, including energy infrastructure investments. The company produces metallurgical and steam coal in a variety of basins throughout the United States and it leases coal through its Elk Horn subsidiary. Rhino Resources has a geographically diverse asset base with coal reserves located in Central Appalachia, Northern Appalachia, the Illinois Basin and the Western Bituminous region. For more information, visit the company's website at www.rhinolp.com.
RiceBran Technologies (RIBT)
RiceBran Technologies (NASDAQ: RIBT) is a technology food company focused on the procurement, bio-refining and marketing of numerous products derived from rice bran. RiceBran Technologies has proprietary and patented intellectual property that converts rice bran, one of the world's most underutilized food sources, into highly nutritious human food ingredients and functional foods. Target markets include human food manufacturers, functional food and supplement manufacturers and animal nutrition manufacturers, both domestically and internationally. The finished product formulas utilize RiceBran Technologies' proprietary and patented ingredients to target nutraceutical and functional food markets worldwide. For more information, visit the company's website at www.ricebrantech.com.
Staffing 360 Solutions (STAF)
Staffing 360 Solutions (NASDAQ: STAF) is engaged in the acquisition of domestic and international staffing organizations. Through this high growth buy-and-build model, the company has expanded from roughly $5 million in revenues in 2013 to over $145 million in revenues on a current annualized basis. The company's veteran management team is focused on converting its pipeline of acquisitions targets into M&A transactions that will fuel the company's growth past its publicly stated goal of achieving $300 million in revenue. For more information, visit the company's website at www.staffing360solutions.com.
TapImmune (OTC: TPIV) is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases. The company's peptide or nucleic acid-based immunotherapeutics comprise one or more naturally processed epitopes designed to comprehensively stimulate patients' T-cells while restoring or further augmenting antigen presentation. TapImmune's technologies are suitable for use as stand-alone medications, as well as in combination with current treatment modalities. For more information, visit the company's website at www.tapimmune.com.
Yangtze River Development (YERR)
Yangtze River Development (OTC: YERR) primarily engages in the business of real estate development with a port logistics project located in the middle reaches of the Yangtze River, strategically positioned in a crucial trading window between China, the Middle East and Europe. To be fully built upon completion of three phases, within the logistics center, there will be six operating zones, including port operation area, warehouse and distribution area, cold chain logistics area, rail cargo loading area, exhibition area and residential community. For more information, visit the company's website at www.kirinintl.com.cn.